Tag Archives: HER2 +Ve breast cancer
FDA Has Granted Enhertu Breakthrough Therapy Designation (BTD) for Adult Patients with Unresectable/Metastatic HER2 +Ve Breast Cancer
The Food and Drug Administration has granted Enhertu (trastuzumab deruxtecan) Breakthrough Therapy Designation (BTD) in the US to treat adult […]
